Columbus Circle Investors lessened its holdings in shares of Illumina (NASDAQ:ILMN) by 6.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 97,963 shares of the life sciences company’s stock after selling 6,496 shares during the period. Columbus Circle Investors owned about 0.07% of Illumina worth $23,160,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ILMN. Jackson Square Partners LLC grew its position in shares of Illumina by 263.0% during the 4th quarter. Jackson Square Partners LLC now owns 1,034,454 shares of the life sciences company’s stock worth $226,017,000 after purchasing an additional 749,468 shares in the last quarter. Jennison Associates LLC grew its position in shares of Illumina by 8.8% during the 4th quarter. Jennison Associates LLC now owns 4,412,621 shares of the life sciences company’s stock worth $964,114,000 after purchasing an additional 355,200 shares in the last quarter. Prudential Financial Inc. grew its position in shares of Illumina by 75.9% during the 1st quarter. Prudential Financial Inc. now owns 762,186 shares of the life sciences company’s stock worth $180,196,000 after purchasing an additional 328,886 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Illumina by 371.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 212,160 shares of the life sciences company’s stock worth $46,355,000 after purchasing an additional 167,206 shares in the last quarter. Finally, Carillon Tower Advisers Inc. acquired a new position in shares of Illumina during the 4th quarter worth approximately $33,752,000. Hedge funds and other institutional investors own 91.59% of the company’s stock.

ILMN has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $270.00 price target for the company in a report on Monday, April 16th. ValuEngine raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday, March 10th. Citigroup raised shares of Illumina from a “neutral” rating to a “buy” rating and upped their price target for the stock from $260.00 to $275.00 in a report on Monday, February 5th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $265.00 price target (up previously from $255.00) on shares of Illumina in a report on Wednesday, January 31st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $251.14.

Shares of Illumina opened at $268.45 on Friday, Marketbeat.com reports. The company has a market capitalization of $38.77 billion, a P/E ratio of 67.11, a P/E/G ratio of 2.71 and a beta of 0.86. The company has a quick ratio of 2.41, a current ratio of 2.71 and a debt-to-equity ratio of 0.23. Illumina has a one year low of $264.12 and a one year high of $267.94.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, April 24th. The life sciences company reported $1.45 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.02 by $0.43. The business had revenue of $782.00 million during the quarter, compared to the consensus estimate of $744.30 million. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The firm’s revenue was up 30.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.64 EPS. research analysts forecast that Illumina will post 4.87 earnings per share for the current fiscal year.

In related news, CEO Francis A. Desouza sold 2,100 shares of the stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of $268.63, for a total value of $564,123.00. Following the completion of the transaction, the chief executive officer now owns 87,371 shares of the company’s stock, valued at approximately $23,470,471.73. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Omead Ostadan sold 1,329 shares of the stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $222.66, for a total transaction of $295,915.14. Following the completion of the transaction, the executive vice president now directly owns 29,392 shares of the company’s stock, valued at approximately $6,544,422.72. The disclosure for this sale can be found here. In the last three months, insiders sold 16,614 shares of company stock valued at $4,018,424. 0.54% of the stock is owned by insiders.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.